Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know

Key Takeaways On April 28, 2026, Gilead finalized its $7.8 billion purchase of Arcellx, securing complete ownership of anito-cel, a CAR T-cell treatment for multiple myeloma. The stock is revisiting breakout levels from an 11-year cup base formation around $123.47, with one market watcher projecting a climb to $173 by December — representing potential upside of 35%. Shares have dropped 8% during April but remain up 22% year-over-year, currently hovering near $128. Technical indicators show GILD’s RSI at 27, marking its most oversold reading in over 12 months, while the 200-day moving average provides nearby support. While the acquisition will reduce both GAAP and non-GAAP earnings per share by $5.57–$5.67 in 2026, projections indicate positive contributions starting in 2028, contingent on regulatory clearance. Gilead Sciences finalized its Arcellx takeover on April 28, offering $115 cash per share alongside a $5 contingent value right. The transaction valued Arcellx’s equity at roughly $7.8 billion at closing. Gilead Sciences, Inc., GILD This acquisition grants Gilead complete ownership of anitocabtagene autoleucel (anito-cel), an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. The two companies had previously partnered through Kite, Gilead’s cellular therapy division. By acquiring Arcellx completely, Gilead removes future royalty commitments, milestone payments, and profit-sharing arrangements. This streamlined structure enables more agile decision-making regarding development timelines and market launch strategies. The contingent $5 CVR payment per share triggers only if anito-cel generates cumulative worldwide sales reaching $6 billion between its launch date and December 31, 2029. While challenging, this threshold demonstrates Gilead’s optimism about the therapy’s revenue potential. Cindy Perettie, who leads Gilead’s Kite division, emphasized the priority is now “executing with speed and discipline” while preparing anit...